PTC Therapeutics CLO Mark Boulding sells $12,337 in stock
PTC Therapeutics' Chief Legal Officer Mark Boulding recently sold 192 shares of company stock on October 9, 2026. This sale, valued at $12,337, occurred concurrently with the purchase of 192 shares through stock options. The stock traded at $59.92, nearing its 52-week low. PTC Therapeutics is currently considered undervalued based on InvestingPro's analysis, appearing on their list of Most Undervalued stocks.
Boulding now owns 105,272 shares of the company. His transactions were executed under a pre-approved Rule 10b5-1 trading plan.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
